Compendium of the most significant studies with reference to properties, intake, effects.
Cortese F, Gesualdo M, Cortese A, Carbonara S, Devito F, Zito A, Ricci G, Scicchitano P, Ciccone MM. Rosuvastatin: Beyond the cholesterol-lowering effect. Pharmacol Res. 2016 May;107:1-18. doi: 10.1016/j.phrs.2016.02.012.
Abstract
Rosuvastatin is a fully synthetic statin wich acts by interfering with the endogenous synthesis of cholesterol through competitively inhibiting the 3-hydroxy-3-methylglutaryl coenzyme A reductase, a liver enzyme responsible of the rate-limiting step in cholesterol synthesis. When compared to other molecules of the same class, it shows high efficacy in the improvement of lipid profile, and, thanks to its non-cholesterol-lowering actions (anti-inflammatory, antioxidant and antithrombotic), represents a crucial tool for cardiovascular primary and secondary prevention. Moreover, recent data highlight rosuvastatin beneficial effects in several other fields. In this manuscript we analyzed literature sources in order to better define rosuvastatin features and discuss some critical issues.
Wander GS, Hukkeri MYK, Yalagudri S, Mahajan B, Panda AT. Rosuvastatin: Role in Secondary Prevention of Cardiovascular Disease. J Assoc Physicians India.
Abstract
Cardiovascular (CV) diseases are a major cause of premature death and disability. Non-communicable diseases (NCD) are responsible for 52% of mortality amongst Indians, of these CV diseases are responsible for 66% of NCD mortality in India. We not only need widespread primary preventive strategy but also need effective secondary prevention protocols to reduce this. Secondary prevention in patients who already had myocardial infarction (MI) or revascularization is of utmost importance to reduce mortality, cardiac events and improve quality of life. Lifestyle changes and medical therapy have a very important role in secondary prevention of CVD. Optimal control of hypertension, diabetes mellitus and dyslipidemia plays a critical role in secondary prevention. Statins are one of the most commonly used drugs in secondary prevention as a part of medical therapy. Effective LDL reduction, more patients achieving LDL goals, reduction in intima thickness, improvement in endothelial dysfunction, reduction in inflammatory markers are considered to be surrogate markers of reduced risk with statins. Rosuvastatin is one of the two most commonly used statins. It is a potent, effective and safe HMG-COA reductase inhibitor. Data related to secondary prevention is limited with rosuvastatin. Most of the clinical evidences with rosuvastatin have shown more effective LDL reduction than other statins. More number of patients achieve LDL goals and reduction in intima thickness. This article attempts to explore data on role of rosuvastatin for secondary prevention.
Rhee MY, Kim KJ, Kim SH, Yoon YW, Rha SW, Hong SJ, Kwak CH, Kim W, Nam CW, Park TH, Hong TJ, Park S, Ahn Y, Lee N, Jeon HK, Jeon DW, Han KR, Moon KW, Chae IH, Kim HY, Kim HS. Ezetimibe and Rosuvastatin Combination Treatment Can Reduce the Dose of Rosuvastatin Without Compromising Its Lipid-lowering Efficacy. Clin Ther. 2019 Dec;41(12):2571-2592. doi: 10.1016/j.clinthera.2019.10.010.
Frommherz L, Has C. Successful treatment of Pachyonychia congenita with Rosuvastatin. J Eur Acad Dermatol Venereol. 2020 Sep;34(9):e480-e482. doi: 10.1111/jdv.16393.
Gao Y, Li L, Yu J, Zhang Z. Rosuvastatin protects PC12 cells from hypoxia/reoxygenation-induced injury by inhibiting endoplasmic reticulum stress-induced apoptosis. Exp Ther Med. 2021 Oct;22(4):1189. doi: 10.3892/etm.2021.10623.
Anderson K, Nelson CH, Gong Q, Alani M, Tarnowski T, Othman AA. Assessment of the Effect of Filgotinib on the Pharmacokinetics of Atorvastatin, Pravastatin, and Rosuvastatin in Healthy Adult Participants. Clin Pharmacol Drug Dev. 2021 Sep 1. doi: 10.1002/cpdd.1015.
Lee SA, Kim W, Hong TJ, Ahn Y, Kim MH, Hong SJ, Kim BS, Kim SY, Chae IH, Kim BJ, Rhee MY, Shin JH, Kang TS, Cho JM, Kim JS, Lee CW. Effects of Fixed-Dose Combination of Low-Intensity Rosuvastatin and Ezetimibe Versus Moderate-Intensity Rosuvastatin Monotherapy on Lipid Profiles in Patients With Hypercholesterolemia: A Randomized, Double-Blind, Multicenter, Phase III Study. Clin Ther. 2021 Aug 21:S0149-2918(21)00261-7. doi: 10.1016/j.clinthera.2021.07.016.
Dihydroxy monocarboxylic acid
